I would like some feedback on the question as to why concordia has the sole rights to manufacure and distribute t3 why there could potentially be another company that could produce. Our own.
boots contract manufacturing in beeston is regulated by the mrha and contracts for proctor and gamble and glaxo smith kline and reckitt and benckiser as well as making a well known face serum you can look younger whilst you feel 90 lol it is also owned by walgreens as a mother company that has its own chain of pharmacys and i think they own jaysons as well boots scientists created ibuprofen and called it neurofen then sold it to reckitts but my point is boots still manufatured it under its own licence under contract
if t3 is a prescription generic drug that potentially could be manufactured some where else alot cheaper as the formula would be available as is ibuprofen then it could potentially be used more as a the cost wouldnt be an issue to the nhs and concordia would not have the strangehold and could be undercut thus making it a better alternative to just t4 for us and the nhs
also these companies all use the workplace sick system of getting people into the dole queue as in the unavailability to work if they made t3 then we wouldnt be as sick and they would have a great workfore
how much would it cost to get another pharmacuetical company to manufacture to a charity the charity supplies all the evidence from members private lab tests and we do our own researce and development and our own paper as to the value of having t3 when you a patient needs it
Can we get a different pharmaceutical company on board i meen they are greedy after all
I might start drinking decaf
Written by
vanillamiller
To view profiles and participate in discussions please or .
so in theory anyone or any new founded or existing charity can register a new or sister limited pharma company at companies house get vat registered cost out formula packaging distribution apply for a licence get bcm to manufacture under contract then create awareness to nhs and then supply? At the same time collating all evidence from the charity and its members and the improvements to life on t3 and being competition to concordia
incidently bcm have a specials department that makes very rare medications
Certainly I cannot see any fundamental reason that it could not be done. If I wanted to get product to market, I'd probably try to find an existing manufacturer and see if they would supply me as an importer.
The organisation would have to buy-in experienced staff - think they would have to include at least a suitable pharmacist. Might find the required insurance premiums eye-watering!
Any really big lottery winners who are dying of boredom on their fourth cruise this year, can't find any more cars they want to buy, have enough homes with electric gates and walk-in wardrobes, bars, hot tubs, etc. This would be a worthwhile spend. Have to face the possibility of losing the entire investment, though.
i am suggesting it may not be as expensive as everyone assumes it costs approx £200 for a limited company name and registration and approx £100 to get vat registered the company could stay dormant providing you provide the accounts the formula is generic so no researce and development costs just licence unknown cost unknown raw materials manufacture costs unknown and distribution however as awful as i hate writing this clearly there is a demand so an existing company could be enticed to produce t3 or anew company set up
Cytomel was owned by Jones, later bought up by King, who in turn were bought up by Pfizer where that formulation and brand remains. The tablets have KPI on them which was, I think, inherited from King Pharnmaceutical.
Glaxo developed Tertroxin, became Glaxo Smith Kline and sold Tertroxin to Goldshield. Goldshield later became Mercury Pharma, part of Amdipharm and now part of Concordia International.
One problem I can forsee is that as T3 in uk is a prescription only med and NHS dogma says it is unnecessary and have always fought prescribing it as a result, any potentially interested manufacturer is likely to say there is not a big enough market to ofset setup costs or licencing costs ☹️☹️
You guys need to get advice from a uk pharma regulatory expert as to why other pharma companies aren't making it.
There are many reasons behind the stranglehold.. .but predominant answer is that EU companies cannot manufacture the exact same formulation and simply import it over.
It would need new clinical trials as....for reasons I can't go in to....they cannot simply make the same drug as the drug company in the headlines makes today....it has to be the same....ie same excipients, same way of manufacture etc.....the law is clear on this ....
Otherwise they would have to prove it is as effective....which means spending money ....a lot of money on trials and using outdated techniques...
Whilst the existing manufacturer can simply drop the price overnight to make it completely unattractive....a big gamble if you are an honourable generic company with small margins
Concordia are now owned by the Rothschild family which has been linked to ruling the modern day world they funded the napoleonic war from Both sides and started banking as we know it today if they say no it’s a no for the masses
Would be funny if that were true, but reality is that it is owned by thousands of ordinary people who were conned in to buying shares, and banks who will never get their money back, meaning that we all end up paying higher interest rates and getting fewer dividends. Check the class action going through the courts at the moment in the USA and Canada. It was called buy to grow strategy, and it made a handful very rich and some others lose their life savings. Now rated as dollar shares and pretty much worthless. Sad...very sad if you got caught up in it.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.